Danaher (NYSE:DHR) Releases Quarterly Earnings Results

Danaher (NYSE:DHR - Get Free Report) issued its earnings results on Tuesday. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16, Zacks reports. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm posted $1.72 EPS. Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher updated its FY 2025 guidance to 7.700-7.800 EPS.

Danaher Trading Up 1.5%

Shares of NYSE:DHR traded up $3.07 during midday trading on Friday, hitting $205.88. The company had a trading volume of 1,944,233 shares, compared to its average volume of 4,246,409. Danaher has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a current ratio of 1.62, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. The stock has a market cap of $147.34 billion, a price-to-earnings ratio of 43.74, a PEG ratio of 2.75 and a beta of 0.77. The firm has a fifty day simple moving average of $196.19 and a 200 day simple moving average of $204.15.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DHR shares. JPMorgan Chase & Co. dropped their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. Leerink Partners raised their price target on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a report on Wednesday, April 23rd. Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. The Goldman Sachs Group dropped their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Finally, Wolfe Research dropped their price target on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a report on Monday, April 7th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.